| 刘晓红.血清AMH、TRACP5b表达水平联合检测对更年期女性发生骨质疏松症的预测价值研究[J].安徽医药,待发表. |
| 血清AMH、TRACP5b表达水平联合检测对更年期女性发生骨质疏松症的预测价值研究 |
|
| 投稿时间：2023-08-25 录用日期：2023-11-29 |
| DOI： |
| 中文关键词: 抗苗勒管激素 抗酒石酸酸性磷酸酶5b 预测价值研究 骨质疏松症 |
| 英文关键词: |
| 基金项目:首都医科大学附属北京世纪坛医院科研课题（2018-q36） |
|
| 摘要点击次数: 263 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：本文研讨血清抗繆勒氏管激素（AMH）、抗酒石酸酸性磷酸酶5b（TRACP5b）水平联合检测对更年期女性发生骨质疏松症的预测价值。方法：选取163例2020年5月至2022年5月在本院诊治的更年期女性为研究对象，将其分为骨质疏松组（n=60）、骨量减少组（n=49）、骨量正常组（n=54）。运用全自动免疫分析仪和酶联免疫吸附法（ELISA）分别检测血清AMH、TRACP5b表达水平；采用Pearson法分析骨质疏松患者血清AMH、TRACP5b水平的相关性；血清AMH、TRACP5水平对更年期女性发生骨质疏松症的预测价值运用受试者工作特征（ROC）曲线进行评估。结果：骨质疏松组、骨量减少组、骨量正常组更年期女性骨密度（BMD）比较，有显著性差异（P＜0.05）；与骨量正常组、骨量减少组相比，骨质疏松组血清AMH表达水平较低，血清TRACP5b水平高于骨量减少组、骨量正常组（P＜0.05）；骨质疏松患者血清AMH、TRACP5b水平呈负相关性（r=-0.420，P＜0.05）；血清AMH、TRACP5b预测更年期女性发生骨质疏松症的曲线下面积（AUC）分别为0.816、0.857，灵敏度分别为81.67%、70.00%，特异度分别为77.78%、88.89%；血清AMH、TRACP5b联合检测预测更年期女性发生骨质疏松症的AUC（0.935）高于各指标单独检测（Z二者联合-AMH=2.359，Z二者联合-TRACP5b=2.515，P=0.018、0.012）。结论：血清AMH、TRACP5b二者联合检测可较好的预测更年期女性骨质疏松症的发生，为更年期女性骨质疏松的为临床治疗提供实验依据。 |
| 英文摘要: |
| Objective: To explore the predictive value of combined detection of serum levels of anti Mullerian hormone (AMH) and tartrate resistant acid phosphatase 5b (TRACP5b) for occurrence of osteoporosis in menopausal women. Methods: A total of 163 menopausal women who were diagnosed and treated in our hospital from May 2020 to May 2022 were selected as the study subjects. They were grouped into an osteoporosis group (n=60), a bone loss group (n=49), and a normal bone mass group (n=54). Roche electrochemical luminescence immunoassay analyzer was applied to detect serum AMH expression level, enzyme linked immunosorbent assay (ELISA) was applied to measure the expression level of serum TRACP5b; Pearson method was applied to analyze the correlation between serum AMH and TRACP5b levels in patients with osteoporosis; receiver operating characteristic (ROC) curve was applied to evaluate the predictive value of serum AMH and TRACP5 levels for the occurrence of osteoporosis in menopausal women. Results There was no statistically obvious difference in age, height, weight, and body mass index (BMI) among menopausal women in the osteoporosis group, osteopenia group, and normal bone mass group (P>0.05), while there was a obvious difference in bone density (BMD) among the three groups (P<0.05); the serum AMH level in the osteoporosis group was lower than that in the osteopenia group and normal bone mass group, while the serum TRACP5b level was higher than that in the osteopenia group and normal bone mass group (P<0.05); the serum levels of AMH and TRACP5b in patients with osteoporosis showed a negative correlation (r=-0.420, P<0.05); the area under the curve (AUC) of serum AMH and TRACP5b in predicting the occurrence of osteoporosis in menopausal women was 0.816 and 0.857, respectively, with sensitivity of 81.67% and 70.00%, and specificity of 77.78% and 88.89%, respectively; the AUC predicted by combined detection of serum AMH and TRACP5b (0.935) for osteoporosis in menopausal women was higher than that of individual detection for various indicators (Z combination-AMH=2.359, Z combination-TRACP5b=2.515, P=0.018, 0.012). Conclusion: The combined detection of serum AMH and TRACP5b can effectively predict the occurrence of osteoporosis in menopausal women, providing experimental basis for clinical treatment of osteoporosis in menopausal women. |
|
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
